What's Driving Gilead Sciences' Growth-Through-Acquisition Strategy
This hasn't been the biggest year for mergers and acquisitions in the biopharmaceutical space, but an inability to meet with colleagues in real life hasn't stopped Gilead Sciences (NASDAQ: GILD) from making multibillion-dollar deals with cancer drug developers.
The company followed up a $4.9 billion deal to acquire Forty-Seven in March with a $21 billion agreement to acquire Immunomedics (NASDAQ: IMMU). In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Cory Renauer discuss the motivations behind Gilead Sciences' recent acquisitions.
Source Fool.com
